

**REMARKS**

The specification has been amended in accordance with 37 CFR §1.78 to make reference to the International Application from which this application originates and to incorporate by reference the Swedish and U.S. priority applications.

Claims 1-3, 6, 14, 16, 17-19, 22, 23, 31, 33, 36-38 and 41 have been amended to more clearly describe the subject matter that Applicants regard as their invention. No new matter has been added.

Claims 4-5, 7-13, 20-21, 24-30, 34-35, 39-40 and 44-45 have been amended to remove multiple dependencies. Claims 46-52 have been added to restore the subject matter claimed in claims 4-5, 7-13, 20-21, 24-30, 34-35, 39-40, 44-45 that was removed as a result of the amendment. The amendment is made to reduce filing fees and not for any other reason related to patentability of such claim. No new matter is added by this amendment.

Furthermore, "use claims" appropriate for European filing were amended more appropriately for US filing. For example, original claims 1-13 were amended to "method claims" (claims 1-13) and "pharmaceutical composition claims" (new claims 53-65). The amended and new claims are supported by the original claims and the specification. No new matter has been added.

In view of the above amendment, Applicants request that pending claims be examined.

Dated: December 10, 2004

Respectfully submitted,

By 

Chris T. Mizumoto

Registration No.: 42,899

DARBY & DARBY P.C.

P.O. Box 5257

New York, 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicants